Profile data is unavailable for this security.
About the company
Vimian Group AB is a Sweden-based veterinary company. The Company is a parent company of the group of companies operating with a purpose of improving animal health through science and technology. The Group delivers solutions to veterinary professionals, labs and pet parents around the world. The purpose of Vimian Group is to unite companies in selected niches of animal health and help them grow faster. The Company invests in innovation and new technologies to advance veterinary medicine. The Group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to its networks, advisory services, infrastructure and capital.
- Revenue in SEK (TTM)4.52bn
- Net income in SEK332.05m
- Incorporated2020
- Employees1.20k
- LocationVimian Group ABRiddargatan 19STOCKHOLM 114 57SwedenSWE
- Phone+46 703358449
- Websitehttps://vimian.com/
More ▼
Mergers & acquisitions
| Acquired company | VIMIAN:STO since announced | Transaction value |
|---|---|---|
| I-Vet Srl | -11.31% | -- |
| AllAccem Inc | -37.08% | -- |
Data delayed at least 15 minutes, as of Mar 02 2026 12:22 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Flerie AB | 0.00 | -757.00m | 2.85bn | 2.00 | -- | 0.8441 | -- | -- | -9.76 | -9.76 | 0.00 | 43.60 | 0.00 | -- | -- | -- | -19.86 | -18.21 | -19.95 | -18.51 | -- | -367.55 | -- | -1,314.83 | -- | -0.0489 | 0.0006 | -- | -100.00 | -- | -231.97 | -- | -- | -- |
| Swedencare AB (publ) | 2.69bn | 55.60m | 4.01bn | 613.00 | 71.97 | 0.602 | 10.96 | 1.49 | 0.3488 | 0.3488 | 16.88 | 41.70 | 0.2718 | 3.76 | 9.26 | 4,395,759.00 | 0.5579 | 0.9368 | 0.5818 | 0.9711 | 32.47 | 34.90 | 2.05 | 3.56 | 1.46 | 3.45 | 0.213 | 49.58 | 6.09 | 62.16 | -43.88 | 10.72 | 120.74 | 11.84 |
| BioGaia AB | 1.54bn | 332.76m | 11.00bn | 242.00 | 33.96 | 8.60 | 30.78 | 7.15 | 3.29 | 3.29 | 15.21 | 12.99 | 0.847 | -- | -- | 6,356,066.00 | 18.32 | 15.48 | 20.63 | 16.86 | 73.37 | 73.12 | 21.63 | 26.35 | -- | -- | -- | 133.18 | 8.11 | 15.54 | -5.30 | 13.11 | -25.87 | 24.01 |
| Bonesupport Holding AB | 1.17bn | 142.15m | 13.33bn | 148.00 | 95.06 | 15.58 | 88.93 | 11.35 | 2.13 | 2.13 | 17.59 | 12.99 | 1.23 | 0.6258 | 5.71 | 7,936,899.00 | 14.84 | 12.10 | 17.69 | 14.71 | 92.57 | 91.94 | 12.10 | 11.45 | 3.97 | 7.20 | 0.0133 | -- | 30.70 | 45.38 | 6.28 | -- | 14.34 | -- |
| Vimian Group AB | 4.52bn | 332.05m | 13.94bn | 1.20k | 42.01 | 1.88 | 18.64 | 3.08 | 0.631 | 0.631 | 8.60 | 14.12 | 0.383 | 1.67 | 7.56 | -- | 2.92 | 1.42 | 3.27 | 1.62 | 68.90 | 69.18 | 7.62 | 3.96 | 1.22 | 7.96 | 0.2519 | 0.00 | 13.42 | 42.94 | 74.59 | -9.36 | 21.97 | -- |
| Bavarian Nordic A/S | 9.83bn | 3.49bn | 22.34bn | 1.74k | 6.46 | 1.17 | 4.97 | 2.27 | 30.57 | 30.57 | 85.79 | 168.13 | 0.4732 | 1.34 | 6.08 | 4,274,910.00 | 16.80 | 3.31 | 20.18 | 4.02 | 54.33 | 52.68 | 35.50 | 9.80 | 2.43 | -- | 0.0101 | 0.00 | -19.06 | 53.88 | -33.03 | -- | -8.77 | -- |
| Camurus AB | 2.27bn | 735.57m | 30.12bn | 285.00 | 41.05 | 7.11 | 39.60 | 13.30 | 12.25 | 12.25 | 37.75 | 70.73 | 0.5332 | 1.24 | 5.36 | 7,948,695.00 | 17.31 | 14.26 | 19.13 | 16.65 | 93.11 | 91.95 | 32.47 | 21.07 | 11.78 | -- | 0.0244 | 0.00 | 21.30 | 46.47 | 71.70 | -- | 110.82 | -- |
| ALK-Abello A/S | 9.01bn | 1.71bn | 63.74bn | 2.72k | 40.84 | 7.58 | 29.47 | 7.07 | 5.40 | 5.40 | 28.47 | 29.09 | 0.7296 | 1.19 | 6.63 | 2,319,736.00 | 13.84 | 8.87 | 17.07 | 11.22 | 67.08 | 63.78 | 18.96 | 12.16 | 2.04 | 87.05 | 0.0609 | 11.63 | 14.00 | 12.58 | 46.87 | 116.79 | 10.15 | -- |
Data as of Mar 02 2026. Currency figures normalised to Vimian Group AB's reporting currency: Swedish Krona SEK
16.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 15 May 2025 | 19.17m | 3.64% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 18.14m | 3.45% |
| Swedbank Robur Fonder ABas of 30 Jan 2026 | 12.17m | 2.31% |
| SEB Funds ABas of 15 May 2025 | 9.74m | 1.85% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 7.63m | 1.45% |
| Fj�rde AP-fondenas of 15 May 2025 | 5.75m | 1.09% |
| Grandeur Peak Global Advisors LLCas of 15 May 2025 | 5.47m | 1.04% |
| Case Kapitalf�rvaltning ABas of 30 Jan 2026 | 4.75m | 0.90% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2025 | 2.73m | 0.52% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 2.12m | 0.40% |
More ▼
Data from 31 Dec 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
